[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Endocrinology](https://durgical.com/en/endocrinology/) › [Obesity and lipids](https://durgical.com/en/endocrinology/areas/obesity-lipids/) › Cardiovascular risk and who gets a statin

# Cardiovascular risk and who gets a statin

- Follow-up and treatment

[Statins](https://durgical.com/en/pharmacology/classes/statins/) are among the best medicines against heart attack and stroke. The art is knowing who needs one, how strong, and how low LDL should go.

Updated Nov 16, 2026

## Key points

- Statin without a calculator: ASCVD, LDL ≥190 mg/dL, diabetes aged 40–75, CKD.
- High intensity ≥50% LDL fall; moderate 30–49%.
- Very high risk: LDL under 55 mg/dL and a 50% fall.
- Add-on order: [ezetimibe](https://durgical.com/en/pharmacology/ezetimibe/) → [PCSK9](https://durgical.com/en/biochemistry/enzymes/pcsk9/) inhibitor or [inclisiran](https://durgical.com/en/pharmacology/inclisiran/).
- Most statin muscle aches are nocebo; rechallenge.

On this page

- The basics Key points
- What it is
- How to think about it
- What to know
- Who gets what, in principle (European-style targets)
- Common traps
- Elsewhere in DurgiPedia

- Clinical In the clinic

- Treatment Next step / Initial management

- Study Test yourself

- Connections Connections

## What it is

Statins block [HMG-CoA reductase](https://durgical.com/en/biochemistry/enzymes/hmg-coa-reductase/), the [liver](https://durgical.com/en/anatomy/liver/) 's [cholesterol](https://durgical.com/en/biochemistry/molecules/cholesterol/) factory; the liver answers by making more LDL receptors and pulling LDL out of the blood. Each fall in LDL cholesterol reduces cardiovascular events in proportion, whatever the starting value. Who gets a statin depends on the absolute risk of an event: people with atherosclerotic disease, LDL of 190 mg/dL or more, diabetes in mid-life or [chronic kidney disease](https://durgical.com/en/conditions/chronic-kidney-disease/) are treated directly; everyone else is treated according to a calculated 10-year risk. Intensity and LDL targets rise with risk.

## How to think about it

Treat the risk, not the number. Picture LDL as the time the artery wall is exposed to cholesterol trucks: the lower and the longer, the fewer crashes. The higher the patient's risk, the more each truck removed is worth, so high risk earns stronger treatment and a lower target.

## What to know

- Risk tools combine age, sex, smoking, [blood pressure](https://durgical.com/en/physiology/systolic-diastolic-mean-and-pulse-pressure/), cholesterol and diabetes: Framingham, the US pooled cohort or PREVENT equations, European SCORE2 and the WHO regional charts.
- Imported risk tools miscalibrate in other populations; Colombian guidance has used a Framingham score adjusted to the Colombian population.
- Statin without a calculator: established atherosclerotic disease, LDL of 190 mg/dL or more, diabetes in adults aged 40–75, and moderate to severe chronic kidney disease.
- Intensity in principle: high intensity lowers LDL by 50% or more, moderate by 30–49%; higher doses of [atorvastatin](https://durgical.com/en/pharmacology/atorvastatin/) or [rosuvastatin](https://durgical.com/en/pharmacology/rosuvastatin/) reach high intensity.
- European targets by risk: very high under 55 mg/dL (1.4 mmol/L) with a 50% fall, high under 70 mg/dL, moderate under 100 mg/dL, low under 116 mg/dL.
- Risk enhancers that favour treatment: family history of premature disease, high Lp(a), [metabolic syndrome](https://durgical.com/en/conditions/metabolic-syndrome/), chronic inflammatory disease, HIV, early [menopause](https://durgical.com/en/physiology/menopause/), pre- [eclampsia](https://durgical.com/en/conditions/eclampsia/).
- A coronary artery calcium score can reclassify intermediate risk: a score of zero can justify waiting, except in smokers, diabetes and [familial hypercholesterolaemia](https://durgical.com/en/conditions/familial-hypercholesterolemia/).
- Add-ons when the target is not met: ezetimibe first, then a PCSK9 inhibitor or inclisiran; [bempedoic acid](https://durgical.com/en/pharmacology/bempedoic-acid/) when statins are not tolerated; [bile acid sequestrants](https://durgical.com/en/pharmacology/classes/bile-acid-sequestrants/) rarely.
- For residual [high triglycerides](https://durgical.com/en/endocrinology/high-triglycerides-and-the-pancreatitis-threshold/) in high-risk patients on a statin, [icosapent ethyl](https://durgical.com/en/pharmacology/icosapent-ethyl/) reduced events; [fibrates](https://durgical.com/en/pharmacology/classes/fibrates/) did not, and are kept mainly to prevent pancreatitis.

## Who gets what, in principle (European-style targets)

| Risk category | Examples | Statin | LDL target |
| --- | --- | --- | --- |
| Very high | Coronary, cerebrovascular or [peripheral arterial disease](https://durgical.com/en/conditions/peripheral-artery-disease/); diabetes with organ damage; severe kidney disease | High intensity, plus add-ons as needed | Under 55 mg/dL and a 50% fall |
| High | LDL 190 mg/dL or more or familial hypercholesterolaemia; long-standing diabetes; moderate kidney disease; high calculated risk | High intensity | Under 70 mg/dL and a 50% fall |
| Moderate | Intermediate calculated risk; young people with short-duration diabetes | Moderate intensity if risk or enhancers justify it | Under 100 mg/dL |
| Low | Low calculated risk | Lifestyle; drug rarely | Under 116 mg/dL |

## In the clinic

- Most muscle aches on statins are not caused by the statin: in blinded trials the same symptoms appeared on placebo, and most patients tolerate a rechallenge.
- True statin myopathy is uncommon and [rhabdomyolysis](https://durgical.com/en/conditions/rhabdomyolysis/) rare; risk rises with [hypothyroidism](https://durgical.com/en/conditions/hypothyroidism/), kidney disease, old age, and interacting drugs ([gemfibrozil](https://durgical.com/en/pharmacology/gemfibrozil/), some [macrolides](https://durgical.com/en/pharmacology/classes/macrolides/) and azoles with [simvastatin](https://durgical.com/en/pharmacology/simvastatin/)).
- Statins slightly raise the chance of diabetes in people already close to it; the cardiovascular benefit is much larger.
- Stable fatty liver and mildly raised liver enzymes are not reasons to withhold a statin; routine monitoring of muscle enzymes is not needed.
- Statins are stopped before conception and in pregnancy.

## Next step / Initial management

- Baseline [lipid profile](https://durgical.com/en/endocrinology/reading-a-lipid-profile/), ALT, [glucose](https://durgical.com/en/biochemistry/molecules/glucose/) or [HbA1c](https://durgical.com/en/biochemistry/topics/glycated-haemoglobin/), [creatinine](https://durgical.com/en/biochemistry/molecules/creatinine/) and TSH; measure CK only if muscle symptoms appear.
- Calculate 10-year risk (skip it in established disease, familial hypercholesterolaemia and LDL of 190 mg/dL or more) and agree the target with the patient.
- Start a statin of the intensity the risk demands; check the lipid profile 4–12 weeks later, then yearly; add ezetimibe if the target is not met.
- Refer to a lipid clinic or endocrinology for suspected familial hypercholesterolaemia, targets not met on statin plus ezetimibe, true intolerance to several statins, or very high Lp(a).

## Common traps

- **Muscle pain on a statin proves statin intolerance**: blinded trials show most symptoms also occur on placebo, so rechallenge with another statin or lower intensity before labelling.
- **The LDL is «normal» so no statin is needed**: decisions follow absolute risk, and a patient with a heart attack benefits from lowering any LDL further.
- **Risk calculators work in every patient**: they underestimate risk in familial hypercholesterolaemia and are not used once atherosclerotic disease is present.
- **Fibrates are the next step when the statin is not enough**: on top of a statin they did not reduce cardiovascular events; ezetimibe and PCSK9-targeted drugs did.
- **Statins damage the liver, so check enzymes often**: serious [liver injury](https://durgical.com/en/conditions/liver-injury/) is very rare and stable fatty liver may even benefit, so one baseline ALT is enough.

## Test yourself

Think of the answer, then tap the question to see it.

## A 62-year-old had a heart attack; his LDL is 98 mg/dL on moderate-intensity statin. What do you do?

Switch to a high-intensity statin and aim for LDL under 55 mg/dL with a 50% fall; add ezetimibe if the target is still not met.

## A woman stopped her statin because of leg aches; CK is normal. What is the best next step?

Rechallenge after a washout with another statin or a lower intensity: most aches are not caused by the statin and most patients then tolerate one.

## A 50-year-old with LDL 200 mg/dL has a low Framingham risk. Does he need a statin?

Yes: LDL of 190 mg/dL or more means probable familial hypercholesterolaemia, and risk calculators underestimate risk in it.

## Why are add-ons such as ezetimibe preferred over fibrates in a statin-treated patient above target?

Because the benefit follows LDL lowering: ezetimibe and PCSK9-targeted drugs lowered LDL and events, while fibrates on top of statins did not cut events.

[Add to my cards (4)](https://durgical.app/estudiar/?add=/en/endocrinology/cardiovascular-risk-and-who-gets-a-statin/)

## Elsewhere in DurgiPedia

- [Cholesterol synthesis (mevalonate pathway)](https://durgical.com/en/biochemistry/pathways/cholesterol-synthesis/)
- [LDL receptor](https://durgical.com/en/biochemistry/enzymes/ldl-receptor/)
- [PCSK9](https://durgical.com/en/biochemistry/enzymes/pcsk9/)
- [Cholesterol](https://durgical.com/en/biochemistry/molecules/cholesterol/)
- [Atherosclerosis: risk factors](https://durgical.com/en/general-pathology/atherosclerosis-risk-factors/)
- [Consequences of atherosclerosis](https://durgical.com/en/general-pathology/consequences-of-atherosclerosis/)

## Connections

## Related 5

- [Reading a lipid profile](https://durgical.com/en/endocrinology/reading-a-lipid-profile/)
- [Spotting familial hypercholesterolaemia](https://durgical.com/en/endocrinology/spotting-familial-hypercholesterolaemia/)
- [Secondary causes of dyslipidaemia](https://durgical.com/en/endocrinology/secondary-causes-of-dyslipidaemia/)
- [The metabolic syndrome: criteria and what they predict](https://durgical.com/en/endocrinology/the-metabolic-syndrome-criteria-and-what-they-predict/)
- [Diabetes complications: what to check and how often](https://durgical.com/en/endocrinology/diabetes-complications-what-to-check-and-how-often/)

## Related conditions 4

- [Atherosclerosis and dyslipidaemia](https://durgical.com/en/conditions/atherosclerosis-and-dyslipidaemia/)
- [Familial hypercholesterolemia](https://durgical.com/en/conditions/familial-hypercholesterolemia/)
- [Type 2 diabetes mellitus](https://durgical.com/en/conditions/type-2-diabetes-mellitus/)
- [Metabolic syndrome](https://durgical.com/en/conditions/metabolic-syndrome/)

## In Pharmacology 11

- [Statins](https://durgical.com/en/pharmacology/classes/statins/)
- [Atorvastatin](https://durgical.com/en/pharmacology/atorvastatin/)
- [Rosuvastatin](https://durgical.com/en/pharmacology/rosuvastatin/)
- [Simvastatin](https://durgical.com/en/pharmacology/simvastatin/)
- [Ezetimibe](https://durgical.com/en/pharmacology/ezetimibe/)
- [Cholesterol absorption inhibitors](https://durgical.com/en/pharmacology/classes/cholesterol-absorption-inhibitors/)
- [PCSK9 inhibitors](https://durgical.com/en/pharmacology/classes/pcsk9-inhibitors/)
- [Inclisiran](https://durgical.com/en/pharmacology/inclisiran/)
- [Bempedoic acid](https://durgical.com/en/pharmacology/bempedoic-acid/)
- [Icosapent ethyl](https://durgical.com/en/pharmacology/icosapent-ethyl/)
- [Fibrates](https://durgical.com/en/pharmacology/classes/fibrates/)

[← All of endocrinology](https://durgical.com/en/endocrinology/)

Educational content; it does not replace a medical assessment and is not a clinical instruction. For confusion, persistent vomiting with diabetes, fainting or very low blood pressure in someone who takes or has stopped glucocorticoids, go to an emergency department at once.

Sources: [Statin Medications](https://www.ncbi.nlm.nih.gov/books/NBK430940/) (StatPearls (NCBI Bookshelf), 2024); [Hyperlipidemia](https://www.ncbi.nlm.nih.gov/books/NBK559182/) (StatPearls (NCBI Bookshelf), 2023); [Hypercholesterolemia](https://www.ncbi.nlm.nih.gov/books/NBK459188/) (StatPearls (NCBI Bookshelf), 2023); [PCSK9 Inhibitors](https://www.ncbi.nlm.nih.gov/books/NBK448100/) (StatPearls (NCBI Bookshelf), 2024); [Lipoprotein A](https://www.ncbi.nlm.nih.gov/books/NBK570621/) (StatPearls (NCBI Bookshelf), 2024).

## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake

Representative model, for educational purposes only.

---
Source: https://durgical.com/en/endocrinology/cardiovascular-risk-and-who-gets-a-statin/
License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/endocrinology/cardiovascular-risk-and-who-gets-a-statin/
